Tempus AI, Inc.
TEM
株式のランク
#1873
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
株価
$64.74
最終同期: 2026-10-19
時価総額
$11.35B
変化（1日）
0.03%
変化（1年）
-29.97%
国
US
取引 Tempus AI, Inc. (TEM)
カテゴリー
Healthcare
Tempus AI, Inc.（TEM）の利益
Jun 2026 時点の利益 TTM: $-259.89M
Tempus AI, Inc. の最新の財務報告によると、同社の現在の利益は $-259.89M です。2023 年には $-213.83M の利益を上げ、これは 2022 年の利益 $-289.75M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Tempus AI, Inc. の利益の推移（2019 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-259.89M | -63.16% |
| 2024 | $-705.54M | 229.96% |
| 2023 | $-213.83M | -26.20% |
| 2022 | $-289.75M | 11.79% |
| 2021 | $-259.19M | 23.51% |
| 2020 | $-209.85M | 82.56% |
| 2019 | $-114.95M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $2.04B | -886.09% |
US
|
|
| $266.26M | -202.45% |
AU
|
|
| $295.53M | -213.71% |
US
|
|
| $-74.89M | -71.18% |
US
|
|
| - | - |
US
|
